Skip to main content
SpringerLink
Log in

Dyslipidemia and Angiotensin II and Atherogenesis

  • Conference paper
The Local Cardiac Renin Angiotensin-Aldosterone System

Part of the book series: Basic Science for the Cardiologist ((volume 20))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chen J, Mehta JL. Role of oxidative stress in coronary heart disease. Indian Heart Journal. 2004;56:163–73.

    PubMed  Google Scholar 

  2. Griendling KK, Minieri CA, Ollerenshaw JD, Alezander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148.

    PubMed  CAS  Google Scholar 

  3. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the rennin-angiotensin system. Circulation. 1999;99:2027–2033.

    PubMed  CAS  Google Scholar 

  4. Freinman PC, Mitchell GC, Heisted DD, Armstrong ML, Harrison DG. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res. 1986;58:783–789.

    Google Scholar 

  5. Minor RLJ, Myers PR, Guerra RJ, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 1990;86:2109–2116.

    PubMed  CAS  Google Scholar 

  6. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J. Clin. Invest. 1991;88:1785–1792.

    Article  PubMed  CAS  Google Scholar 

  7. Aviram M. Modified forms of low-density lipoprotein and atherosclerosis. Atherosclerosis. 1993;98:1–9.

    Article  PubMed  CAS  Google Scholar 

  8. Keidar A, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular biosynthesis. Atherosclerosis. 1999;146:249–257.

    Article  PubMed  CAS  Google Scholar 

  9. Nickenig G, Baumer AT, Temur Y, et al. Distinct and combined vascular effects of ACE blockade HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719–725.

    Google Scholar 

  10. Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci. 1998;63:1–11.

    Article  PubMed  CAS  Google Scholar 

  11. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996;16:97–105.

    PubMed  CAS  Google Scholar 

  12. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999;84:1043–1049.

    PubMed  CAS  Google Scholar 

  13. Keidar A, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular biosynthesis. Atherosclerosis. 1999;146:249–257.

    Article  PubMed  CAS  Google Scholar 

  14. Mitanchi H, Bandoh T, Kumura M, Totsuka T, Hayashi S. Increased activity of vascular ACE related to atherosclerosis lesions in hyperlipidemic rabbits. Am J Physiol. 1996;271:H1065–H1071.

    Google Scholar 

  15. Yang BC, Phillips MI, Mohuczy D, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1433–1439.

    PubMed  CAS  Google Scholar 

  16. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–1378.

    PubMed  CAS  Google Scholar 

  17. Gross CM, Gerbaulet S, Quensel C, et al. Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis. Basic Res Cardiol. 2002;97:327–333.

    Article  PubMed  CAS  Google Scholar 

  18. Nickenig G, Sachinidis A, Seewald S, Bohm M, Vetter H. Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens. 1997;15(suppl 6):S27–S30.

    Google Scholar 

  19. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappa B. Circulation. 2000;102:1970–1976.

    PubMed  CAS  Google Scholar 

  20. Wassman S, Nickenig G, Bohm M. HMG-CoA reductase inhibitor atorvastatin downregulates AT1 receptor gene expression and cell proliferation in vascular smooth muscle cells. Kidney Blood Press Res. 1999;21:392–393.

    Google Scholar 

  21. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131–2134.

    PubMed  CAS  Google Scholar 

  22. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyasaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;412:86–90.

    Article  PubMed  CAS  Google Scholar 

  23. Ehara S, Ueda M, Naruka T, et al. Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960.

    PubMed  CAS  Google Scholar 

  24. Mehta JL, Li D. Identification, regulation and function of a novel lectin like oxidized low-density lipoprotein receptor. J Am Coll Cardiol. 2002;39:1429–1435.

    Article  PubMed  CAS  Google Scholar 

  25. Moriwakitt H, Kume N, Kataoka H, et al. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett. 1998;440:29–32.

    Article  Google Scholar 

  26. Murase T, Kume N, Korenaga R, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:329–333.

    Google Scholar 

  27. Li DY, Yang BC, Mehta JL. Ox-LDL induces apoptosis in cultured human coronary artery endothelial cells: role of PKC, PTK, bc1-2, and Fas. Am J Physiol. 1998;275:H568–H576.

    PubMed  CAS  Google Scholar 

  28. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20:1116–1122.

    PubMed  CAS  Google Scholar 

  29. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–2895.

    PubMed  CAS  Google Scholar 

  30. Li D, Yang B, Philips MI, Mehta JL. Pro-apoptotic effects of angiotensin II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am J Physiol. 1999;276: H786–H792.

    PubMed  CAS  Google Scholar 

  31. Mehta JL, Li D. Facilitative interaction between angiotensin II and oxidized LDL in cultured human coronary artery endothelial cells. J Renin Angiotensin Aldosterone Syst. 2001;2:D70–S76.

    Google Scholar 

  32. Chen H, Li D, Sawamura T, Inoue K, Mehta JL. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun. 2000;276:1100–1104.

    Article  PubMed  CAS  Google Scholar 

  33. Chen LY, Haught WH, Yang BC, Saldeen TGP, Parathasarathy S, Mehta JL: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effect of vitamin E, lovastatin and amlodipine. JACC 30:569–575, 1997.

    PubMed  CAS  Google Scholar 

  34. Mehta JL, Li DY, Chen HJ, et al. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun. 2001;289:857–861.

    Article  PubMed  CAS  Google Scholar 

  35. Li D, Chen H, Romeo F, et al. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther. 2002;302:601–605.

    Article  PubMed  CAS  Google Scholar 

  36. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res. 2002;35:1001–1015.

    Article  PubMed  CAS  Google Scholar 

  37. N. Ohkubo, H. Matsubara, Y. Nozawa et al., Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96 (1997), pp. 3954–3962.

    PubMed  CAS  Google Scholar 

  38. Jugdutt BI, Xu Y, Balghith M, Moudgil R, Menon V. Cardioprotection induced by AT1R blockade after reperfused myocardial infarction: association with regional increase in AT2R, IP3R and PKCepsilon proteins and cGMP. J Cardiovasc Pharmacol Ther. 2000;5:301–311.

    PubMed  CAS  Google Scholar 

  39. Li D, Mehta JL. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium. 2003;10:17–21.

    Article  PubMed  Google Scholar 

  40. Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Int Med. 2003;163:1296–1304.

    Article  CAS  Google Scholar 

  41. Chatterjee S. Role of oxidized human plasma low density lipoproteins in atherosclerosis: effects on smooth muscle cell proliferation. Molecular Cellular Biochemistry. 1992;111:143–147.

    CAS  Google Scholar 

  42. Bjorkerud B, Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc B iol. 1996;16:416–424.

    CAS  Google Scholar 

  43. Joseph J, Ranganathan S, Mehta JL. Low-density lipoproteins modulate collagen metabolism in fibroblasts. J Cardiovasc Pharmacol Therap 2003;8:161–6.

    CAS  Google Scholar 

  44. Ridker PM, Brown NJ, Harrison DG, Mehta JL, Vaughn DE. Established and emerging plasma biomarkers in the prediction of first atherothrombotic event. Circulation 2004:109(25 Suppl 1):IV6–IV19.

    PubMed  Google Scholar 

  45. Chen J, Li D, Witztum J, Miller E, Mehta JL. A specific antibody against ox-LDL, Cu-LDL-IgG, may serve as a marker for predictor of atherosclerosis. Circulation 2004 (in press).

    Google Scholar 

  46. Hayek T, Attias J, Coleman R, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res. 1999;44:579–587.

    Article  PubMed  CAS  Google Scholar 

  47. Leif SJ, Karin P, Gunnar A, Rolf GGA, Bengt EK, Anders GO. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol. 1994;24:670–677.

    Article  Google Scholar 

  48. Bavry AA, Li D, Zander DS, Phillips MI, Mehta JL. Inhibition of arterial thrombogenesis by quinapril but not losartan. J Cardiovasc Pharmacol Ther. 2000;5:121–127.

    Article  PubMed  CAS  Google Scholar 

  49. Becker RH, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol. 1991;18:S110–S115.

    PubMed  CAS  Google Scholar 

  50. Farhy RD, Carretro OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202–1210.

    PubMed  CAS  Google Scholar 

  51. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol. 2003 May 1;91(9):1116–9.

    Google Scholar 

  52. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092–1103.

    PubMed  CAS  Google Scholar 

  53. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapmanz MJ. Matrix metalloproteinases and atherosclerosis. Annales de Biologie Clinique. 2003;61:147–158.

    PubMed  CAS  Google Scholar 

  54. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Inazu A, Mabuchi H. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 201;39:380–384.

    Google Scholar 

  55. Nahmod KA, Vermeulen ME, Raiden S, Nahmod V, Giordano M, Geffner JR. Control of dendritic cell differentiation by angiotensin II. FASEB Journal. 2003; 17:491–493.

    PubMed  CAS  Google Scholar 

  56. Schonbeck U, Gerdes N, Ganz P, Kinlay S, Libby P. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002; 106:2888–2893.

    Article  PubMed  CAS  Google Scholar 

  57. Chen H, Mehta JL. Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2002; 39:332–339.

    Article  PubMed  CAS  Google Scholar 

  58. Bellosta S, Via D, Canavesi M, Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998; 18:1671–1678.

    PubMed  CAS  Google Scholar 

  59. Werle M. Schmal U. Hanna K. Kreuzer J. MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res. 2002; 56:284–292.

    Article  PubMed  CAS  Google Scholar 

  60. Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, Wilson PWF, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med. 1999;159:2206–2212.

    Article  PubMed  CAS  Google Scholar 

  61. Sung BH, Izzo JI, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens. 1997;10:592–599.

    Article  PubMed  CAS  Google Scholar 

  62. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719–725.

    PubMed  CAS  Google Scholar 

  63. O’Callaghan CJ, Krum H, Conway EL, et al. Short-term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press. 1994;3:404–406.

    PubMed  CAS  Google Scholar 

  64. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin): a pilot study. Schweiz Med Wochenschr. 1998;128:272–277.

    PubMed  CAS  Google Scholar 

  65. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 2000;36:El–E2.

    Google Scholar 

  66. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramirez JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:1497–1499.

    Article  PubMed  CAS  Google Scholar 

  67. Borghi C, Prandin MG, Costa FV, Baccheli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35:549–555.

    Article  PubMed  CAS  Google Scholar 

  68. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980–987.

    Article  PubMed  CAS  Google Scholar 

  69. Jonkers IJ, de Man FH, van der Laarse A, et al. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens. 2001;19:749–755.

    Article  PubMed  CAS  Google Scholar 

  70. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction). Circulation. 1996;94:258–265.

    PubMed  CAS  Google Scholar 

  71. Pitt B, O’Neill B, Feldman R, et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87:1058–1063.

    Article  PubMed  CAS  Google Scholar 

  72. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000;35:89–95.

    Article  PubMed  CAS  Google Scholar 

  73. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial, the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Internal Medicine and Physiology and Biophysics, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA

    Muhammad T. Gill MD, Jaiwei Chen MD & J. L. Mehta MD, PhD

Authors
  1. Muhammad T. Gill MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaiwei Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. L. Mehta MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA, 70121, USA

    Edward D. Frohlich M.D.  & Richard N. Re M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this paper

Cite this paper

Gill, M.T., Chen, J., Mehta, J.L. (2006). Dyslipidemia and Angiotensin II and Atherogenesis. In: Frohlich, E.D., Re, R.N. (eds) The Local Cardiac Renin Angiotensin-Aldosterone System. Basic Science for the Cardiologist, vol 20. Springer, Boston, MA. https://doi.org/10.1007/0-387-27826-5_12

Download citation

  • DOI: https://doi.org/10.1007/0-387-27826-5_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-27825-4

  • Online ISBN: 978-0-387-27826-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation